Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

is not a substitute for immunohistochemistry (IHC) testing to find patients who may have HER2 amplification that does not appear on NGS. She shared data for trastuzumab deruxtecan (Enhertu ...

To diagnose triple-positive breast cancer, doctors will test a biopsy sample for hormone receptors and HER2 levels. A doctor may use an immunohistochemistry (IHC) test to check cancer cells for ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the globa ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

HER2 IHC 3+ staining was observed in 15 (4.7%) of the 320 tumor samples analyzed and HER2 IHC 2+ in 26 (8.1%; Table 1). Low HER2 expression (IHC 0 or 1+) was detected in the 279 (87.2% ...